|
|
Renal Studies Currently Recruiting Participants at the SimmonsCooper Cancer Research Center at Southern Illinois University School of Medicine
| Protocol Title |
Study # |
Study Group |
| ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma |
ECOG E2805 |
CICCOP |
| Treatment of High Risk Renal Tumors |
COG AREN0321 |
SIU COG |
| Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor |
COG AREN0532 |
SIU COG |
| Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors |
COG AREN0533 |
SIU COG |
| The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma [BeST] |
ECOG E2804 |
CICCOP |
Although our objective is to provide an updated listing of available clinical trials please note that a listing here does not guarantee that a trial is open or available to any specific patient and that there may be additional trials available that are not listed. Complete information is only available from a treating physician.
Contact Information:
SimmonsCooper Cancer Institute Clinical Trials Office
Mail Code 9677 Fax (217) 545-6823
- Kathy Robinson, PhD, Director of Clinical Trials
(217) 545-1946
- Susan Klug, RN, OCN
(217) 545-7929
- Jennifer Bekker RN, BSN
(217) 545-2219
-
SIU COG
- Carol Peterson, RN, CCRP (217) 545-7377
SIU IM
- Amanda Fogleman, B.A. (217) 545-0592
- Cathy Naritoku, M.S., RD (217)545-8078
-
SIU Thoracic
- Theresa Boley, RN, MSN, APN/FNP-BC, CCRP (217) 545-5000
-
- Cathy Leslie, RN (217) 545-8184
- Cheryl Ogden, RN, CCRC (217) 545-7474
-
RTOG: Radiation Therapy Oncology Group:
- Diana Weyhenmeyer, RN, M.A., OCN (217) 544-6464 ext. 45591
CICCOP: Central Illinois Community Clinical Oncology Program
Memorial Medical Center CICCOP Research Contacts:
Treatment/Cancer Control:
- Holly Thomas (217) 788-4178
- Stephanie Allbritton (217) 788-3544
- Brooke Trickey (217) 217-788-3560
- Karen Graber (217) 588-2961
- Chrissy Tucker (217) 788-4444
Back to Open Clinical Trials
|
 |
|
